Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (520)	3/7/2005 12:08:22 PM
From: keokalani'nui	Respond to of 946

>>Is pixantrone P2 data contaminated by his virus? Is it reliable?<< Not yet, as good data was produced by the seller before ctic acquired it last year.

To: quidditch who wrote (520)	3/7/2005 12:11:55 PM
From: Icebrg	Read Replies (1) \| Respond to of 946

Pixantrone appears to be a much safer bet. (I know I am not supposed to write such things, but old habits etc...). For Pixantrone there are a number of clinical studies with good-looking results for the indication, that is now the subject of the registration trial. The problem with Xyotax and what me very suspicious to start with was that there was really no relevant phase II results. But as the survival in the Stellar trials over time became so much better than anything seen so far, my reservations disappeared. I was pretty convinced that Stellar 3 would become a success for the longs. Unfortunately, that was not the case. The strongest point (in my mind) in favour of Xyotax was however the fact that NovusPharma agreed to become merged into and diluted by CTIC. They should have been able to do the proper DD for us shareholders. Evidently, they didn't do a good enough job. Which just shows how difficult this is. Even for someone with access to much more information and experience than what we have. It will really be interesting to find out what went wrong with the trial. Erik